Stalk versus base invasion in pT1 papillary cancers of the bladder: improved substaging system predicting the risk of progression Aims: Pathological stage pT1 bladder cancers constitute a clinically heterogeneous group. However, current staging guidelines for superficially invasive cancers do not acknowledge the variability in type and extent of lamina propria invasion in papillary urothelial carcinomas (PUCs), and historically proposed substaging systems showed either high interobserver variation or limited value in predicting patient outcomes. The aim of this study was to reappraise pT1 PUC substaging, with the objective of identifying a novel scheme that is reproducible and prognostically meaningful. Methods and results: pT1 PUCs diagnosed during 1999-2015 were retrospectively reviewed and characterized as focal invasion confined to the papillary stalk, focal invasion of the tumour base, or extensive invasion of the tumour base. Cases with concurrent flat carcinoma in situ, angiolymphatic invasion, absent muscularis propria or clinically advanced disease were excluded. We calculated cumulative incidence rates of recurrence, progression and death by tumour subtype, and evaluated differential risks by using log-rank tests and Kaplan-Meier curves stratified by type and extent of invasion. Among 62 patients satisfying the inclusion criteria, 22 of 29 patients with base-extensive invasion progressed, whereas four of 13 with base-focal and none of 20 with stalk-only invasion progressed. There was strong evidence that base-extensive patients had a higher risk of progression and death resulting from bladder cancer than base-focal or stalk-only patients (P < 0.0001). However, tumour subtype was not significantly associated with risk of recurrence (P = 0.21). Conclusions: We propose an innovative substaging approach for reporting the site and extent of lamina propria invasion in patients with pT1 PUC, allowing patient stratification for risk of progression.
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Introduction
Three-quarters of newly diagnosed cases of bladder tumour are exophytic papillary urothelial carcinomas (PUCs) that are either confined to the epithelium (pTa) or invade only the lamina propria (LP) (pT1). 1 These tumours are generally managed with transurethral resection, with or without adjuvant intravesical therapy. 2 However, approximately 50-70% of patients with such tumours have a recurrence or a new urothelial carcinoma in the bladder within 5 years. 3 Although pT1 bladder cancers are heterogeneous with respect to outcomes, current guidelines for superficially invasive cancers do not discriminate between different levels of LP invasion. 4, 5 Several substaging systems were proposed, but showed high interobserver variation, a lack of consensus on criteria, and an inability to segregate lesions that focally and superficially invade the papillary stalk. 1, [6] [7] [8] [9] [10] [11] [12] Some studies have shown improved survival for patients with pT1 lesions treated with immediate cystectomy, [13] [14] [15] but others have not shown a benefit. 16 Thus, there remains an interest in identifying high-risk patients within the pT1 group who would benefit most from cystectomy.
The majority of PUCs of the bladder have a stalk composed of loose connective tissue with fine capillaries, some inflammatory cell infiltrate, and oedema, which has a distinct appearance histologically and on magnetic resonance imaging. 17 The composition of the tumour base differs from that of the stalk, owing to overgrowth of denser fibrous tissue, the presence of pulled-in superficial muscular bundles, increased fibroblastic proliferation, and inflammation of adjacent thickened bladder wall. 17 We employed an innovative practical approach to papillary pT1 substaging by separating invasion of the LP into the stalk from base invasion, either focal or extensive, and evaluated outcomes over a moderate follow-up period.
Materials and methods

C A S E S E L E C T I O N
The pathology archives of the University of Washington Medical Center (UWMC) were searched for primary PUC diagnoses during the period 1999-2015, and this yielded 285 transurethral resections of bladder tumours (TURBTs) with either definite LP invasion (pT1) or suspicion of LP invasion (pTa or pT1). After database analysis and slide review by the primary pathologist (M.L.), cases with a predominantly non-papillary configuration, concurrent flat carcinoma in situ (CIS), angiolymphatic space invasion, micropapillary features, absent muscularis propria, prior intravesical therapy or clinically advanced disease were excluded. Sixty-two cases satisfied the selection criteria. These were independently re-reviewed by a specialized genitourinary pathologist (M.T.), and divided into three pT1 groups: (i) invasion confined to the papillary stalk (n = 20, 32%); (ii) focal invasion of the tumour base (n = 13, 21%); or (iii) extensive (multifocal) invasion of the tumour base (n = 29, 47%). The morphological features of stalk-only invasive PUC were similar to those that have been previously described, 18 with either unifocal or multifocal involvement of oedematous loose connective stroma of papillary stalks free of muscle fascicles, dense collagen, vascular plexus, and a cautery effect (Figure 1) . Base invasion was divided into focal and extensive categories according to previously proposed morphological criteria, 8 with modifications tested in a larger-scale recent multi-institutional study. 1 The base-focal category was defined as either a single focus of microinvasion of size <1 mm, or more than one microinvasive focus, all visible within one 920 high-power field (HPF), corresponding to an area of 1 mm. The base-extensive category was defined as either a single microinvasive focus of size >1 mm, or two or more foci of invasion that were >1 mm from each other or present in multiple tissue fragments.
All patients were treated and followed up at a single academic institution (UWMC) in accordance with the American Urological Association guidelines for non-muscle-invasive bladder cancer. The treatment included intravesical therapy for the majority of patients (60%), with bacillus Calmette-Guerin immunotherapy (70%) or mitomycin (30%), re-TURBT (8%), partial or total cystectomy (26%), and active surveillance (6%) because of other comorbidities, including coagulopathy, prior history of tuberculosis, and frequent infections. The most common approach was patient reassessment with urine cytology and cystoscopy every 3 months in the first 2 years after initial diagnosis, then every 6 months for the subsequent 2 years, and then annually thereafter (https://www.auanet.org/education/guidelines/ bladder-cancer.cfm).
S T A T I S T I C A L A N A L Y S I S
Differences in patient and tumour characteristics across tumour subtypes were evaluated with the Kruskal-Wallis test for continuous characteristics or Fisher's exact test for categorical characteristics. Recurrence was defined as the reappearance of a histologically confirmed non-muscle-invasive PUC (including pTa or pT1). Recurrence-free survival (RFS) was defined as the time from primary treatment to the first documented evidence of any non-muscleinvasive papillary cancer, with censoring at the first progression event, other-cause death, or last followup. Progression was defined as the development of muscle-invasive (pT2) or higher-stage carcinoma, distant metastasis, or multifocal refractory-to-treatment pT1 disease with CIS. Progression-free survival (PFS) was defined as the time from primary treatment to the first documented progression event, with censoring at other-cause death or last follow-up. Event-free survival (EFS) was defined as time from primary treatment to the earlier of first documented progression event or first documented recurrence event with censoring at other-cause death or last follow-up. Cause-specific survival was defined as the time from primary treatment to death resulting from bladder cancer, with censoring at other-cause death or last follow-up. Overall survival (OS) was defined as the time from primary treatment to death from any cause, with censoring at last follow-up. Survival endpoints were evaluated across tumour subtypes, between patients with age at diagnosis above and below the median age, and between patients with tumour size above and below the median tumour size, and differential risks were evaluated with Kaplan-Meier estimation and log-rank tests. A subset analysis repeated these estimations and tests, excluding low-grade cases. Univariate Cox proportional hazards models were fitted to evaluate associations between tumour subtypes and the survival endpoints. Cumulative incidence rates of follow-up procedures for progression, types of progression, types of recurrence and causes of death were calculated across tumour subtypes with the R package CMPRSK (Gray B. cmprsk: Subdistribution analysis of competing risks: R package version 2.2-7; http://cran.r-project.org/packa ge=cmprsk). Bonferroni adjustment was performed for tests involving these three endpoints; consequently, only P-values of <0.05/3 = 0.017 were considered to be statistically significant. In contrast to the stalk, base connective stroma (E-L) was more condensed and eosinophilic, with obvious muscularis mucosa fascicles, prominent vasculature, increased inflammatory infiltrate, and sometimes a marked desmoplastic response. The base-focal category was defined as a single focus of microinvasion within one 920 high-power field (HPF) corresponding to a 1-mm area (E-H). The base-extensive category was defined as either a few microinvasive foci >1 mm apart, present in multiple tissue fragments, or invasion of an area that would not fit within one 920 HPF (I-L).
2016). This retrospective study utilizing existing human specimens, data and clinical information did not require contact with participants, and was therefore approved with a waiver of consent as per the guidelines of the UWMC Human Subjects Division.
Results
Sixty-two patients with primary pT1 PUC met all of the selection criteria, and included 48 (77%) male and 14 (23%) female patients. The median age at diagnosis was 69 years (range 44-95 years), with some variation across the patient groups. A total of 20 patients met the criteria for stalk-only, 13 for base-focal, and 29 for base-extensive (Table 1 ; Figure 1) . Concomitant stalk invasion was noted in two patients with base-focal invasion and in two patients with base-extensive invasion. On average, patients with stalk-only invasion were 4 years older than patients with base-focal invasion and 9 years older than patients with base-extensive invasion. The median follow-up was 3.2 years (range 0.1-16.7 years).
The majority of patients were white (n = 56, 90%), three (5%) were Asian/multiethnic, two (3%) were black, and one (2%) was of unknown race. The majority of pT1 PUCs (n = 57, 92%) were high-grade tumours, and the remaining five (8%) were low-grade tumours, four of which showed stalk-only invasion. The maximum dimension of tumours averaged 20 mm (range 3-90 mm). Table 1 summarizes patient and tumour characteristics for the 62 patients grouped into pT1 subtypes. There was no evidence that clinicopathological characteristics significantly differed across tumour subtypes.
All patients were followed by urine cytology with cystoscopy (n = 59) and follow-up procedures including re-biopsies (n = 18), re-TURBT (n = 12), partial cystectomies (n = 5), cystectomies (n = 18), or lymph node biopsy (n = 1). Cumulative incidence functions (CIFs) for recurrence, progression and death with estimated values over 9 years of follow-up are shown in Table 2 and illustrated by tumour subtype in Figure S1 . Across subtypes, recurrence was observed in 11 patients (CIF 26%) and progression in 29 patients (CIF 51%). There was strong evidence that pT1 subtype was associated with the risk of progression (P < 0.0001), but there was no evidence of association with the risk of recurrence (P = 0.21). More specifically, recurrence was observed in four (CIF 30%) of the stalk-only cohort, four (CIF 51%) of the base-focal cohort, and only three (CIF 10%) of the base-extensive cohort, which had the highest incidence of cystectomies (CIF 48%). None of the pT1 base-focal tumours recurred with a higher substage of pT1 base-extensive. Across subtypes, progression events included base-extensive multifocal pT1 with or without concomitant CIS (n = 8, 14%), pT2 (n = 13, 23%), pT3 (n = 4, 7%), pT4 (n = 2, 3%), and metastatic disease (n = 2, 4%). Strikingly, 86% of baseextensive patients versus 33% of base-focal patients experienced progression within 9 years of follow-up. There were no progression events in the stalk-only group. Over 9 years of follow-up, there were no deaths resulting from bladder cancer among stalk- CI, confidence interval; CIF, cumulative incidence function; CIS, carcinoma in situ; TURBT, transurethral resection of bladder tumour; -, no estimate is available, because no event occurred. *The CIF estimates the 9-year percentage probability of the event. Statistically significant probabilities are those for which the CIs exclude 0.
only patients, there was one death (CIF 13%) among base-focal patients, and there were four deaths (CIF 16%) among base-extensive patients, showing a statistically significant risk of cancer-specific mortality for the base-extensive group. Furthermore, there were three (CIF 30%), four (CIF 54%) and seven (CIF 41%) deaths from causes, respectively. Kaplan-Meier curves and log-rank tests provided strong evidence that PFS and EFS differed across subtypes (both P < 0.0001) (Figure 2 ). The median PFS in the base-extensive patients was 4.1 months [95% confidence interval 3.6-14.3]. The median PFS in the other two groups was not achieved. In contrast, there was no evidence of different RFS across subtypes (P = 0.43). OS did not differ across subtypes (P = 0.61). Exploratory analysis of risks of recurrence or progression by age at diagnosis above or below the median age did not show a significant difference (P = 0.44 and P = 0.49, respectively). Similarly, tumour size above or below the median value of 14 mm was not associated with risks of recurrence or progression (P = 0.99 and P = 0.25, respectively). In our subset analysis, excluding the low-grade cases and repeating the Kaplan-Meier estimations and CIF analyses did not materially affect our conclusions, because four of the five low-grade cases were of the stalk-only subtype, which had few events (data not shown).
Univariate Cox model analyses showed that the extent of lamina propria invasion had a statistically significant impact on tumour recurrence and/or progression, with hazard ratios of 2.8 for base-focal cases and 7.3 for base-extensive cases (P = 0.0002; Table 3 ).
Discussion
We found that the proposed subtyping of PUCs into stalk-only, base-focal and base-extensive groups yielded a promising and practical system for stratifying patients that corresponds with the risk of progression. The greatest benefit of pT1 subtyping was its ability to stratify patients with respect to PFS and EFS (P < 0.0001). In our study, the incidence rates of progression and cancer-specific mortality were lowest in the stalk-only group and highest in the base-extensive group. Although we found no evidence that subtypes were associated with recurrence or OS, this is perhaps unsurprising, given the older age of patients with stalk-only invasion in our study, the limited number of patients, and the overall favourable survival for pT1 patients under moderate follow-up. Our findings are consistent with those of a recent largescale meta-analysis and prospective studies showing significant associations of pT1 substaging with progression and cancer-specific survival but not with recurrence. 15, 19 LP invasion (pT1) remains an area of great interest and controversy, because it adds significantly to the risks of recurrence and progression to muscle-invasive disease. 2, 15 Accumulating data suggest that substaging of pT1 disease is clinically relevant, 15 but there is no agreement about the optimal approach. Several systems have been generated to subclassify LP involvement by level, depth and extent of involvement. These proposals include substaging into pT1 with the muscularis mucosa (MM) and the associated large blood vessels as landmarks. 7, 9, 19, 20 However, owing to substantial individual variation in the MM and the LP vascular plexus, difficulty in the pathological interpretation of small, fragmented, poorly oriented or cauterized tissue, and no identifiable MM in a high percentage of cases, especially in PUC stroma, this approach is highly problematic. 2, 7, 11, 18, 21 Measuring the depth of tumour invasion with a micrometer is another approach, and was originally promoted by Cheng et al. 6 Upon validation, these methods yielded numerous cut-off points of 0.5, 1.0, 1.5, 3.0 and 6.0 mm, all of which were claimed to be significantly associated with outcomes. 2, 6, 10, 18, 22 Other morphometric measurements, such as tumour diameter and aggregate length, were also suggested as prognostic factors with classifications of <3, 3-5 and >5 or >6 mm as significant prognostic variables. 10 Apparently, an objective measurement approach is also not without the significant drawbacks of variable thresholds and cumbersome morphometric assessment, and is thus unlikely to gain wide acceptance.
The novelty of our approach is in separating stalk invasion from base invasion, and further case stratification by invasive tumour extent in PUC. Stalk invasion is viewed as an early stage of tumour invasion, when cells are penetrating the morphologically distinct, loose, often oedematous, connective stroma. These invasive cells and tumour nests are still confined within the exophytic tumour component at a significant distance from the proper bladder wall and associated deeper vasculature, and are thus less likely to spread and progress than tumours invading the PUC base. The significance of separating stalk-invasive tumours was recognized earlier in a few studies, a systematic approach and strict selection criteria were lacking. 7, 23, 24 For instance, studies by Hermann and Tommasini-Degna 7, 23 included in their cohorts cases with associated CIS, thus increasing the numbers of patients but potentially affecting outcomes.
The pT1 tumours were substaged into: pT1a-invasion of the tumour stalk without involvement of the LP under the stalk; pT1b-LP invasion under the tumour stalk but superficial to the MM; and pT1c-invasion into or deeper than the MM without involvement of the muscularis propria. 7 The problem with Progression-free survival was defined as the time from primary treatment to the first documented progression event (stage progression or multifocality with or without concurrent carcinoma in situ) with censoring at other-cause death or last follow-up. Eventfree survival was defined as the time from primary treatment to the earlier of the first documented progression event and the first documented recurrence event (any nonmuscle invasive papillary cancer including pTa or pT1) with censoring at other-cause death or last follow-up.
this approach was a lack of the MM in Σ50% of their cases. Despite this, pathological upstaging to pT2 disease did not occur in cases with stalk-only invasion, in contrast to cases with 'under the stalk invasion'. 7 For base invasion, we modified the previously tested pT1 m/e system of separating focal microinvasive (m) tumours from extensive (e) categories by using the rather simple morphological criterion of a 920 HPF being equivalent to an area of invasion of 1 mm. 1, 2, 8, 25 This system is very practical, could be applied to almost every case, and proved to be reproducible in 81-100% of the tumours. 1, 8, 22 It is of note that we divided our stalk-only invasive cases into focal (80%) and extensive (20%) categories, similarly to base-invasive cases, but the outcomes were identical, so separating the stalk-only cases may not be justified. This observation supports our hypothesis of compositional, anatomical and biological differences between stalk and base stromal invasion, with the latter representing indolent disease that can be successfully treated with TURBT. The significantly higher risk of progression of base-extensive tumours accords with their more aggressive phenotype, potentially deeper bladder wall involvement, and understaging on the initial TURBT. Thus, recognizing and differentiating stalk-invasive from base-focal and base-extensive invasion PUC may convey an important message to clinicians for optimal further disease management.
The strength of our study design is in very stringent selection criteria, whereby we focused on primary PUC, eliminating pT1 cases of non-papillary solid architecture, and cases with concurrent CIS, lymphovascular invasion, absent muscularis propria, or clinically advanced disease. With a few exceptions, the majority of other pT1 substaging studies have grouped together papillary and non-papillary pT1 tumours, as well as pT1 tumours with and without concurrent CIS, as a 'total inclusion' routine to maximize the numbers of cases. 1, 2, 7, 9, 10, 12, 19, 20, 25, 26 Evidently, pT1 tumours with solid architecture arising from CIS are biologically different from papillary pT1 tumours, more frequently show an infiltrative versus a nodular growth pattern, and have a significantly higher risk of progression. 19, 26 The presence of associated CIS further contributes to tumour aggressiveness. 2, 15, 19 Second, our substaging approach is more easily applied to daily practice, with group separation based on the morphological appearance of stroma and a 920 objective for size and multifocality assessment rather than laborious morphometric measurements 6, 10, 12 or ancillary immunohistochemical staining. 27, 28 However, as a result of strict selection criteria and a low incidence of stalk-only PUC, the numbers of patients in our study are relatively low. Excluding urothelial carcinomas with non-papillary architecture also reduces case numbers and represents a limitation of our study. With combined efforts from multiple institutions, it will be important to further validate the reproducibility of our proposed scheme in a larger prospective cohort.
In summary, we have proposed an innovative, practical pT1 substaging system for PUC, and have shown that the site and extent of LP invasion are significantly associated with the risks of progression and prognosis. Tumour invasion limited to the papillary stalk clearly represents a morphologically and prognostically indolent group, and is worth reporting separately from the base-invasive tumours, owing to the minimal risk of progression. In contrast, reporting of extensive base invasion as a significant adverse prognostic factor may be important in identifying patients who are most likely to benefit from more aggressive treatment.
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